Potent and broad anti-HIV-1 activity exhibited by a glycosyl-phosphatidylinositol-anchored peptide derived from the CDR H3 of broadly neutralizing antibody PG16

Journal of Virology

Volumn 85, Issue 17, 2011, Pages 8467-8476

  Liu, Lihong ^a   Wen, Michael ^a   Wang, Weiming ^a   Wang, Shumei ^a   Yang, Lifei ^a   Liu, Yong ^c   Qian, Mengran ^a   Zhang, Linqi ^b   Shao, Yiming ^c   Kimata, Jason T ^d   Zhou, Paul ^a  

^a INSTITUTE PASTEUR OF SHANGHAI   (China)

^b Tsinghua University   (China)

^c CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN MONOCLONAL ANTIBODY AVF; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN MONOCLONAL ANTIBODY B12; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN MONOCLONAL ANTIBODY E51; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN MONOCLONAL ANTIBODY PGI16; NEUTRALIZING ANTIBODY; PEPTIDE; PEPTIDE CDR H3; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL MEMBRANE; CELL SURFACE; CONTROLLED STUDY; DRUG POTENCY; GENE CONSTRUCT; GENE EXPRESSION; GENE TARGETING; GENETIC LINKAGE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIPID RAFT; MOLECULAR CLONING; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VIRUS ATTACHMENT; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS RESISTANCE; VIRUS STRAIN;

ANTIBODIES, NEUTRALIZING; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CLONING, MOLECULAR; GENE EXPRESSION; GLYCOPEPTIDES; GLYCOSYLPHOSPHATIDYLINOSITOLS; HIV ANTIBODIES; HIV-1; HUMANS; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; VIRUS INTERNALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80052284226     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00520-11     Document Type: Article

References (42)

1. Burton, D. R., et al. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024-1027.
2. Carter, G. C., et al. 2009. HIV entry in macrophages is dependent on intact lipid rafts. Virology 386:192-202.
3. Changela, A., et al. 2011. Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1. J. Virol. 85:2524-2535.
4. Chazal, N., and D. Gerlier. 2003. Virus entry, assembly, budding, and membrane rafts. Microbiol. Mol. Biol. Rev. 67:226-237.
5. DiGiusto, D. L., et al. 2010. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(_) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci. Transl. Med. 2:36ra43.
6. Doores, K. J., and D. R. Burton. 2010. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J. Virol. 84:10510-10521.
7. Dorfman, T., M. J. Moore, A. C. Guth, H. Choe, and M. Farzan. 2006. A tyrosine-sulfated peptide derived from the heavy-chain CDR3 region of an HIV-1-neutralizing antibody binds gp120 and inhibits HIV-1 infection. J. Biol. Chem. 281:28529-28535.
8. Follenzi, A., L. E. Ailles, S. Bakovic, M. Geuna, and L. Naldini. 2000. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat. Genet. 25:217-222.
9. Freed, E. O., D. J. Myers, and R. Risser. 1989. Mutational analysis of the cleavage sequence of the human immunodeficiency virus type 1 envelope glycoprotein precursor gp160. J. Virol. 63:4670-4675.
10. He, J., et al. 1995. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J. Virol. 69:6705-6711.
11. Kimata, J. T., L. Kuller, D. B. Anderson, P. Dailey, and J. Overbaugh. 1999. Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression. Nat. Med. 5:535-541.
12. Kothe, D. L., et al. 2007. Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. Virology 360:218-234.
13. Koyanagi, Y., et al. 1987. Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 236:819-822.
14. Kozak, S. L., J. M. Heard, and D. Kabat. 2002. Segregation of CD4 and CXCR4 into distinct lipid microdomains in T lymphocytes suggests a mechanism for membrane destabilization by human immunodeficiency virus. J. Virol. 76:1802-1815.
15. Labrijn, A. F., et al. 2003. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J. Virol. 77:10557-10565.
16. Li, Y., et al. 1991. Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and -defective viral genomes. J. Virol. 65:3973-3985.
17. Liao, Z., L. M. Cimakasky, R. Hampton, D. H. Nguyen, and J. E. Hildreth. 2001. Lipid rafts and HIV pathogenesis: host membrane cholesterol is required for infection by HIV type 1. AIDS Res. Hum. Retroviruses 17:1009-1019.
18. Medof, M. E., T. Kinoshita, and V. Nussenzweig. 1984. Inhibition of complement activation on the surface of cells after incorporation of decayaccelerating factor (DAF) into their membranes. J. Exp. Med. 160:1558-1578.
19. Miller, A. D., and F. Chen. 1996. Retrovirus packaging cells based on 10A1 murine leukemia virus for production of vectors that use multiple receptors for cell entry. J. Virol. 70:5564-5571.
20. Moulard, M., et al. 2002. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc. Natl. Acad. Sci. U. S. A. 99:6913-6918.
21. Nguyen, D. H., B. Giri, G. Collins, and D. D. Taub. 2005. Dynamic reorganization of chemokine receptors, cholesterol, lipid rafts, and adhesion molecules to sites of CD4 engagement. Exp. Cell Res. 304:559-569.
22. Overbaugh, J., R. J. Anderson, J. O. Ndinya-Achola, and J. K. Kreiss. 1996. Distinct but related human immunodeficiency virus type 1 variant populations in genital secretions and blood. AIDS Res. Hum. Retroviruses 12:107-115.
23. Pancera, M., et al. 2010. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternaryspecific antibodies that effectively neutralize HIV-1. J. Virol. 84:8098-8110.
24. Pejchal, R., et al. 2010. Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc. Natl. Acad. Sci. U. S. A. 107:11483-11488.
25. Percherancier, Y., et al. 2003. HIV-1 entry into T-cells is not dependent on CD4 and CCR5 localization to sphingolipid-enriched, detergent-resistant, raft membrane domains. J. Biol. Chem. 278:3153-3161.
26. Platt, E. J., K. Wehrly, S. E. Kuhmann, B. Chesebro, and D. Kabat. 1998. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 72:2855-2864.
27. Popik, W., T. M. Alce, and W. C. Au. 2002. Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4(+) T cells. J. Virol. 76:4709-4722.
28. Prodromou, C., and L. H. Pearl. 1992. Recursive PCR: a novel technique for total gene synthesis. Protein Eng. 5:827-829.
29. Saphire, E. O., et al. 2001. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 293:1155-1159.
30. Shang, H., et al. 2011. Genetic and neutralization sensitivity of diverse HIV-1 ENV clones from chronically infected patients in China. J. Biol. Chem. 286:14531-14541.
31. Simons, K., and E. Ikonen. 1997. Functional rafts in cell membranes. Nature 387:569-572.
32. Stamatatos, L., L. Morris, D. R. Burton, and J. R. Mascola. 2009. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat. Med. 15:866-870.
33. Sun, L., et al. 2009. Generation, characterization and epitope mapping of two neutralizing and protective human recombinant antibodies against influenza A H5N1 viruses. PLoS One 4:e5476.
34. Theodore, T. S., et al. 1996. Construction and characterization of a stable full-length macrophage-tropic HIV type 1 molecular clone that directs the production of high titers of progeny virions. AIDS Res. Hum. Retroviruses 12:191-194.
35. Tsai, C., et al. 2009. Measurement of neutralizing antibody responses against H5N1 clades in immunized mice and ferrets using pseudotypes expressing influenza hemagglutinin and neuraminidase. Vaccine 27:6777-6790.
36. Walker, L. M., et al. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289.
37. Wen, M., et al. 2010. GPI-anchored single chain Fv-an effective way to capture transiently-exposed neutralization epitopes on HIV-1 envelope spike. Retrovirology 7:79.
38. Wu, X., et al. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856-861.
39. Xiang, S. H., et al. 2003. Epitope mapping and characterization of a novel CD4-induced human monoclonal antibody capable of neutralizing primary HIV-1 strains. Virology 315:124-134.
40. Zhou, T., et al. 2010. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329:811-817.
41. Zhou, T., et al. 2007. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445:732-737.
42. Zwick, M. B., et al. 2003. Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120. J. Virol. 77:5863-5876.